SynthesisAddiction science & clinical practice2019
Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders.
Synthesis in Addiction science & clinical practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 108 citations in OpenAlex.
- A community approach to promote healthcare services for people living with HIV who use drugs in Vietnam.International journal of STD & AIDS · 2022Trial
- Exploratory analysis of pharmacist involvement in motivational interviewing intervention for patients with prescription opioid misuse behaviors.JAPhA practice innovations · 2026Article
- Examining rural community pharmacists' knowledge and practices in opioid overdose prevention and treatment services in the Southeastern United States.Harm reduction journal · 2025Article
- Article
- Evaluation of pharmacists' opioid dispensing practices: a cross-sectional study from Pakistan.Journal of pharmaceutical policy and practice · 2025Article
- Transforming Opioid Overdose Prevention in the United States: Leveraging FDA's Narcan Approval to Foster a Culture of Health.Risk management and healthcare policy · 2025Article
- Neurodevelopmental outcomes in children prenatally exposed to opioid maintenance treatment: A population-based study.Pharmacotherapy · 2024Article
- Delivering MOUD to the Underserved: How Can Pharmacies Really Help?Journal of studies on alcohol and drugs · 2024Article
- Patient and pharmacist perspectives on opioid misuse screening and brief interventions in community pharmacies.Addiction science & clinical practice · 2024Article
- Implementing a pharmacist-integrated collaborative model of medication treatment for opioid use disorder in primary care: study design and methodological considerations.Addiction science & clinical practice · 2024Article
- Advancing opioid stewardship in low-middle-income countries: challenges and opportunities.Journal of pharmaceutical policy and practice · 2024Article
- Community Pharmacists' Knowledge and Attitude Towards Opioid Pain Medication Use in Bahir Dar City, North-West Ethiopia.Journal of multidisciplinary healthcare · 2024Article
- Community pharmacists' role towards preventing abuse or misuse and dependence of codeine-containing analgesic medications in Saudi Arabia: a multicenter cross-sectional study.Frontiers in pharmacology · 2024Article
- Perspectives on and experiences of emergency department-initiated buprenorphine among clinical pharmacists: A multi-site qualitative study.Journal of substance use and addiction treatment · 2023Article
- Identifying Prescription-Opioid-Related Risks Using Prescription Drug Monitoring Programs' Algorithms and Clinical Screening Tools.Pharmacy (Basel, Switzerland) · 2023Article
- Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff.Substance abuse treatment, prevention, and policy · 2023Article
- Changes to methadone maintenance therapy in the United States, Canada, and Australia during the COVID-19 pandemic: A narrative review.Journal of substance use and addiction treatment · 2023Review
- Opioid Use Disorder Curricular Content in US-Based Doctor of Pharmacy Programs.American journal of pharmaceutical education · 2023Article
- Community-Centered Patient Journey Map in Opioid Use Disorder: A Tool to Address Compassion Fatigue among Community Pharmacists.Pharmacy (Basel, Switzerland) · 2023Article
- Between Care and Control: Examining Surveillance Practices in Harm Reduction.Contemporary drug problems · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
The global rise in opioid-related harms has impacted the United States severely. Current efforts to manage the opioid crisis have prompted a re-evaluation of many of the existing roles in the healthcare system, in order to maximize their individual effects on reducing opioid-associated morbidity and preventing overdose deaths. As one of the most accessible healthcare professionals in the US, pharmacists are well-positioned to participate in such activities. Historically, US pharmacists have had a limited role in the surveillance and treatment of substance use disorders. This narrative review explores the literature describing novel programs designed to capitalize on the role of the community pharmacist in helping to reduce opioid-related harms, as well as evaluations of existing practices already in place in the US and elsewhere around the world. Specific approaches examined include strategies to facilitate pharmacist monitoring for problematic opioid use, to increase pharmacy-based harm reduction efforts (including naloxone distribution and needle exchange programs), and to involve community pharmacists in the dispensation of opioid agonist therapy (OAT). Each of these activities present a potential means to further engage pharmacists in the identification and treatment of opioid use disorders (OUDs). Through a careful examination of these approaches, we hope that new strategies can be adopted to leverage the unique role of the community pharmacist to help reduce opioid-related harms in the US.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.